Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2019 · 10-Q
Revenue$651.00K$651.00K+325.5% vs Q2 2018 Net Income-$4.47M-$4.47MN/M vs Q2 2018 EPS Diluted-$0.24-$0.24N/M vs Q2 2018 Operating Income-$4,015,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,044,000N/M Margins · derivedOperating margin-616.7%+1623.1 pt vs Q2 2018
Net margin-686.5%+1861.9 pt vs Q2 2018
ended Dec 31, 2018 · filed Feb 13, 2019 · 44 d after period end